Clinical trials: Patients With Speech Disorders
- Condition Patients With Speech Disorders
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Meniere's Disease
SPI-1005 for the Treatment of Patients With Meniere's Disease
This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.
- Trial name
- NCT03325790
- Testing
- 200mg SPI-1005 BID, 400mg SPI-1005 BID
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sound Pharmaceuticals, Incorporated